Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q3 2013 · 10-Q
Revenue$507.38K$507.38K−49.4% vs Q3 2012 Net Income-$9.00M-$9.00MN/M vs Q3 2012 EPS Diluted-$0.16-$0.16N/M vs Q3 2012 Gross Profit$507,384−39.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$6,416,440N/M Free Cash Flowderived-$7,657,358N/M Margins · derivedGross margin100.0%+16.9 pt vs Q3 2012
Operating margin-2010.7%−1418.1 pt vs Q3 2012
Net margin-1774.4%−1280.4 pt vs Q3 2012
ended Sep 30, 2013 · filed Nov 12, 2013 · 43 d after period end